These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 31803478)

  • 21. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
    Yang SC; Lai WW; Lin CC; Su WC; Ku LJ; Hwang JS; Wang JD
    Lung Cancer; 2017 Jun; 108():183-191. PubMed ID: 28625633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON).
    van Iersel CA; de Koning HJ; Draisma G; Mali WP; Scholten ET; Nackaerts K; Prokop M; Habbema JD; Oudkerk M; van Klaveren RJ
    Int J Cancer; 2007 Feb; 120(4):868-74. PubMed ID: 17131307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selection criteria for lung-cancer screening.
    Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
    N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
    Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
    Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Inclusion of More Black Individuals in Lung Cancer Screening With Reduced Mortality.
    Prosper AE; Inoue K; Brown K; Bui AAT; Aberle D; Hsu W
    JAMA Netw Open; 2021 Aug; 4(8):e2119629. PubMed ID: 34427681
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline characteristics of participants in the randomized national lung screening trial.
    ; Aberle DR; Adams AM; Berg CD; Clapp JD; Clingan KL; Gareen IF; Lynch DA; Marcus PM; Pinsky PF
    J Natl Cancer Inst; 2010 Dec; 102(23):1771-9. PubMed ID: 21119104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
    Kumar V; Cohen JT; van Klaveren D; Soeteman DI; Wong JB; Neumann PJ; Kent DM
    Ann Intern Med; 2018 Feb; 168(3):161-169. PubMed ID: 29297005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of risk prediction models to lung cancer screening: a review.
    Tammemägi MC
    J Thorac Imaging; 2015 Mar; 30(2):88-100. PubMed ID: 25692785
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating the Cost-Effectiveness of Lung Cancer Screening with Low-Dose Computed Tomography for High-Risk Smokers in Australia.
    Wade S; Weber M; Caruana M; Kang YJ; Marshall H; Manser R; Vinod S; Rankin N; Fong K; Canfell K
    J Thorac Oncol; 2018 Aug; 13(8):1094-1105. PubMed ID: 29689434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
    Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
    Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency.
    Cressman S; Peacock SJ; Tammemägi MC; Evans WK; Leighl NB; Goffin JR; Tremblay A; Liu G; Manos D; MacEachern P; Bhatia R; Puksa S; Nicholas G; McWilliams A; Mayo JR; Yee J; English JC; Pataky R; McPherson E; Atkar-Khattra S; Johnston MR; Schmidt H; Shepherd FA; Soghrati K; Amjadi K; Burrowes P; Couture C; Sekhon HS; Yasufuku K; Goss G; Ionescu DN; Hwang DM; Martel S; Sin DD; Tan WC; Urbanski S; Xu Z; Tsao MS; Lam S
    J Thorac Oncol; 2017 Aug; 12(8):1210-1222. PubMed ID: 28499861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing Different Approaches to Leveraging Historical Smoking Exposure Data to Better Select Lung Cancer Screening Candidates: A Retrospective Validation Study.
    Kats DJ; Adie Y; Tlimat A; Greco PJ; Kaelber DC; Tarabichi Y
    Nicotine Tob Res; 2021 Aug; 23(8):1334-1340. PubMed ID: 32974635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial.
    Tammemägi MC; Ten Haaf K; Toumazis I; Kong CY; Han SS; Jeon J; Commins J; Riley T; Meza R
    JAMA Netw Open; 2019 Mar; 2(3):e190204. PubMed ID: 30821827
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of lung cancer risk model (PLCO
    Lebrett MB; Balata H; Evison M; Colligan D; Duerden R; Elton P; Greaves M; Howells J; Irion K; Karunaratne D; Lyons J; Mellor S; Myerscough A; Newton T; Sharman A; Smith E; Taylor B; Taylor S; Walsham A; Whittaker J; Barber PV; Tonge J; Robbins HA; Booton R; Crosbie PAJ
    Thorax; 2020 Aug; 75(8):661-668. PubMed ID: 32631933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to general medical checkup and cancer screening guidelines according to self-reported smoking status: Korea National Health and Nutrition Examination Survey (KNHANES) 2010-2012.
    Kim EY; Shim YS; Kim YS; Lee SP; Ko KD; Choi WJ
    PLoS One; 2019; 14(10):e0224224. PubMed ID: 31639166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The performance of NLST screening criteria in Asian lung cancer patients.
    Kumar V; Becker K; Zheng HX; Huang Y; Xu Y
    BMC Cancer; 2015 Nov; 15():916. PubMed ID: 26582178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis.
    Black WC
    J Thorac Imaging; 2015 Mar; 30(2):79-87. PubMed ID: 25635704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of lung MRI in lung cancer screening.
    Allen BD; Schiebler ML; Sommer G; Kauczor HU; Biederer J; Kruser TJ; Carr JC; Hazen G
    Eur Radiol; 2020 Mar; 30(3):1738-1746. PubMed ID: 31748855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
    Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
    PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of CT screening in the National Lung Screening Trial.
    Black WC; Gareen IF; Soneji SS; Sicks JD; Keeler EB; Aberle DR; Naeim A; Church TR; Silvestri GA; Gorelick J; Gatsonis C;
    N Engl J Med; 2014 Nov; 371(19):1793-802. PubMed ID: 25372087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.